Topoisomerase I (TOP1) inhibitors are an important class of anticancer drugs. The cytotoxicity of TOP1 inhibitors can be modulated by replication fork reversal through a process that requires poly(ADP-ribose) polymerase (PARP) activity. Whether regressed forks can efficiently restart and what factors are required to restart fork progression after fork reversal are still unknown. We have combined biochemical and EM approaches with single-molecule DNA fiber analysis to identify a key role for human RECQ1 helicase in replication fork restart after TOP1 inhibition that is not shared by other human RecQ proteins. We show that the poly(ADP-ribosyl)ation activity of PARP1 stabilizes forks in the regressed state by limiting their restart by RECQ1. These studies provide new mechanistic insights into the roles of RECQ1 and PARP in DNA replication and offer molecular perspectives to potentiate chemotherapeutic regimens based on TOP1 inhibition. npg a r t i c l e s npg
a r t i c l e s TOP1 inhibitors are an important class of anticancer drugs that exert their function by perturbing DNA replication 1, 2 . The mechanisms of tumor response to TOP1 inhibitors and combinations of TOP1 inhibitors with other drugs for more effective tumor treatment are areas of active investigation 3, 4 . One widely accepted mechanism for the cytotoxicity of TOP1 inhibitors has been their ability to create single-strand breaks (SSBs), which are converted to toxic DNA double-strand breaks (DSBs) upon colliding with the replication fork during replication 5 . This notion was recently challenged by the discovery that TOP1 inhibitors also impair TOP1 relaxation activity, inducing an accumulation of positive supercoils ahead of the replication fork that may hamper fork progression and the conversion of SSBs to DSBs 1, 6 . Recent studies extended this observation by showing that replication forks rapidly slow and undergo fork reversal upon treatment with clinically relevant doses of camptothecin (CPT), the prototype TOP1 inhibitor 7, 8 . This prevents DSB formation and requires the activity of PARP1, a well-known chromatin-associated enzyme that modifies various nuclear proteins by poly(ADP-ribosyl)ation (PARylation), to accumulate regressed forks 7 . However, the exact role of PARP1 in promoting fork reversal remains unexplained. In addition, other factors are likely to be involved in this process, and the protein(s) required to restore and restart reversed replication forks after the lesion is repaired have not been identified.
RecQ helicases have long been proposed to assist replication forks in dealing with replication stress and have attracted considerable interest in recent years owing to their connection to heritable human diseases associated with cancer predisposition 9, 10 . RecQ helicase enzymatic activities (such as DNA unwinding, branch migration and strand annealing) may have multiple roles during replication by virtue of their ability to interconvert numerous replication and recombination intermediates [11] [12] [13] . Moreover, previous studies have pointed to a potential role of RecQ helicases in fork reversal and restart by showing that two of the five human RecQ helicases, BLM and WRN, promote both regression and re-establishment of model replication forks in vitro [14] [15] [16] . However, distinct roles or molecular functions for the five human RecQ helicases in replication stress and cancer remain to be defined 10, 17 .
For the present study, we combined biochemical, single-molecule DNA fiber and EM approaches to investigate the function of the human RECQ1 helicase (also known as RECQL or RECQL1) during the replication stress response. Of the five human RecQ proteins, RECQ1 was the first to be discovered, owing to its potent ATPase activity, and it is the most abundant in cells 18, 19 . However, little is known about its cellular functions to date. Here, we show that RECQ1 has an essential role-one not shared by other human RecQ helicases-in restoring active replication forks that have regressed as a result of TOP1 inhibition. Moreover, we provide a rationale for the a r t i c l e s requirement of the PARylation activity of PARP1 in replication fork reversal. Our observations give new insight into a pivotal mechanism responsible for replication stress response and replication fork restart after chemotherapeutic drug damage. These findings have important clinical implications, as RECQ1 inactivation might affect the efficacy of combinatorial therapies that employ PARP inhibitors and DNAdamaging agents and are already in promising clinical trials.
RESULTS

RECQ1 interacts with PARP1 and PAR
To better define the role of human RECQ1 helicase in DNA replication and repair, we first identified proteins associated with RECQ1 using a new, integrated proteomic approach 20 . We used human embryonic kidney (HEK293) cells to generate a stable, inducible cell line expressing a doubly tagged version of RECQ1 (consisting of a streptavidin-binding peptide and a hemagglutinin epitope tag), then isolated protein complexes containing RECQ1 by affinity purification ( Supplementary Fig. 1a-d) ; we characterized the resulting complexes by MS 20 . Among the most abundant co-purified proteins were PARP1, Ku70 and Ku80 (key components of the DNA nonhomologous end-joining pathway) and several nucleosomal components ( Supplementary Fig. 1e ). Given recent reports indicating a role for PARP1 in replication stress response 7,21 , we decided to focus our work on defining the role of RECQ1 interactions with PARP1.
We confirmed the RECQ1-PARP1 interaction by coimmunoprecipitation (co-IP) using nuclear extracts from human osteosarcoma (U-2 OS) cells and an antibody to RECQ1 (anti-RECQ1) that recognizes the C terminus of RECQ1 (residues 633-648). We obtained similar results using an anti-RECQ1 antibody that recognizes the N terminus of the protein (data not shown). We also performed reciprocal co-IPs using an anti-PARP1 antibody ( Fig. 1a and Supplementary  Fig. 1f ). All co-IPs were performed in the presence of ethidium bromide or Benzonase to ensure that DNA did not mediate the interactions. We obtained similar results with other cell lines ( Supplementary  Fig. 1f and data not shown), indicating that the association between RECQ1 and PARP1 is not cell-type specific. These observations are in agreement with a previous report showing that RECQ1 and PARP1 interact at viral replication origins and with a recent study reporting an interaction between RECQ1 and PARP1 in human cells 22, 23 .
The RECQ1-PARP1 interaction is regulated by PARP1 PARylation activity: we observed increased association of the two proteins upon DNA damage and sharply reduced association upon inhibition of PARP1 activity with the PARP inhibitor NU1025 ( Fig. 1a and Supplementary Fig. 1g ). Using recombinant, purified PARP1 and RECQ1, we found that these two proteins interact directly, and the interaction was considerably stronger when we used a PARylated form of PARP1, indicating that the PAR modification of PARP1 is important for the interaction with RECQ1 ( Supplementary Fig. 2a,b) . Indeed, we observed that RECQ1 interacted with PAR, and binding to PAR was resistant to extensive washing with 1 M salt, although we could not identify any canonical PAR binding motifs in RECQ1 (ref. 24) ( Supplementary Fig. 2c ). We verified that NU1025 did not affect the interaction between recombinant RECQ1 and PARP1 in vitro, indicating that the reduced RECQ1-PARP1 interaction we observed by co-IP in the presence of this inhibitor is due to the inhibition of PARP1 PARylation activity rather than to a potential effect of NU1025 on PARP conformation (Supplementary Fig. 2b) .
We next mapped the domains of RECQ1 that interact with PARP1 and PAR using a series of glutathione S-transferase (GST)-tagged RECQ1 fragments ( Fig. 1b-d) . Both PARP1 and PAR interacted with the C-terminal region of RECQ1 (residues 391-649; fragment names below indicate residue numbers), which contains the zinc-binding (Zn) and winged helix (WH) domains that form the 'RecQ-C-terminal' (RQC) domain, but not with fragment 391-473, which contains the Zn domain alone (Fig. 1c) . The WH domain alone (fragment 474-649) also bound PARP1, although more weakly than fragment 391-649. These results suggest that the region containing residues 391-473 might be important for the stability and/or conformation of the WH domain. Our data also suggest that the region containing residues 391-649 is PARylated by PARP1 in vitro ( Supplementary Fig. 2d and Supplementary Note); however, RECQ1 does not seem to be PARylated in vivo 22 .
To determine which region(s) of PARP1 are involved in RECQ1 interaction, we overexpressed truncated versions of PARP1 fused to Figure 1 Analysis of the RECQ1-PARP1 interaction. (a) Immunoprecipitation from U-2 OS cells using the anti-RECQ1 antibody with (+) or without (−) NU1025 (50 µM) and with CPT (100 nM for 2 h) or without DNA damage (mock). Rabbit IgG IP served as a negative control. Immunoblots were developed with anti-RECQ1 and anti-PARP1 antibodies. (b) Schematic representation of the domain structure of RECQ1 and the GST-tagged RECQ1 fragments. D1 and D2, RecA-like domains. (c) Pulldown assays with GST-tagged RECQ1 fragments. Top, Coomassie-stained gel of GST-RECQ1 fragments. Bottom, autoradiography of in vitro GST pulldown assay using 35 S-labeled PARP1. MW, molecular weight (kDa). (d) Analysis of PAR binding to GST-RECQ1 fragments (2 pmol) dot-blotted onto a nitrocellulose membrane. The arrows indicate the two RECQ1 fragments that interact with 32 P-labeled PAR. (e) Schematic representation of the domain structure of PARP1 and the GST-tagged PARP1 fragments: A, DNA binding domain; B, nuclear localization signal; D, BRCT automodification domain; E, contains a WGR motif; F, catalytic domain; FI and FII, zincfinger motifs; NLS, nuclear localization sequence. A third zinc-finger motif has been recently identified in domain C 36, 37 in addition to FI and FII. (f) Pulldown assays with GST-tagged PARP1 (GST-PARP) fragments. Bound proteins were detected by autoradiography (bottom). Purified GST or GST-PARP1 proteins were detected with an anti-GST antibody (top). Input, 20% of the amount used in binding reactions. a r t i c l e s GST in HeLa cells ( Fig. 1e,f) . Only fragments 1-371 and 384-524 could efficiently pull down RECQ1 in immunoprecipitation experiments, and fragment 174-366 did not pull down RECQ1. These results indicate that the interaction with RECQ1 involves the first 173 N-terminal residues of PARP1 (containing the DNA binding domain) and residues 384-524 (containing the BRCT domain, which is also the automodification domain). These two PARP1 domains are also involved in homodimerization and the binding of several partners, including WRN helicase 25, 26 .
RECQ1 catalyzes restoration of synthetic replication forks
On the basis of the recent discovery that PARP1 has an important role in reversal of replication forks after CPT treatment 7 , we investigated whether RECQ1 is required for the cellular response to TOP1 inhibition. First, we confirmed previous observations that RECQ1 depletion leads to increased CPT sensitivity 27 . Flow-cytometric analysis showed that RECQ1-depleted cells are only mildly sensitive to most replication inhibitors and DNA-damaging agents, apart from CPT and etoposide ( Supplementary Fig. 3a and Supplementary Note). These two drugs inhibit DNA replication by suppressing the relaxation activity of the type IB and type IIA topoisomerases, respectively 2 . Next, to confirm that RECQ1 binds to replication forks in vivo and that the interaction increases upon CPT treatment, we labeled newly replicated DNA with 5-chlorodeoxyuridine (CldU), and confirmed RECQ1 co-IP with CldU in the presence and absence of CPT ( Supplementary Fig. 3b and Supplementary Note).
We then tested whether RECQ1 mediates replication fork regression and/or restoration on synthetic DNA substrates and whether PARP1 affects RECQ1 activity. To measure these RECQ1 activities in vitro, we used a set of four oligonucleotides that can anneal into two alternative substrates that mimic model replication fork and 'chickenfoot' structures 14, 28 (Supplementary Fig. 3c and Supplementary  Table 1 ). We found that RECQ1 promotes model replication fork restoration very efficiently and in a concentration-dependent fashion: 50 nM RECQ1 converted >75% of the chicken-foot structure into the model replication fork after 20 min ( Fig. 2a,b) . In contrast, RECQ1 failed to catalyze the opposite reaction (fork regression): we detected <2% of chicken-foot structure, even at the highest RECQ1 concentration. We obtained identical results using a variant of the same substrate lacking the 6-nucleotide (nt) single-stranded DNA (ssDNA) gap on the leading-strand template, thus ruling out the possibility that the presence of the ssDNA gap prevented RECQ1-mediated fork regression ( Supplementary Figs. 3d and 4a) . Next, we confirmed that the ATPase activity of RECQ1 is essential to promote branch migration of the chicken-foot structure and restoration of the active replication fork. We observed that the poorly hydrolyzable ATP analog ATPγS and the nonhydrolyzable analog AMP-PNP strongly inhibited the reaction, and two previously characterized ATPase-deficient RECQ1 mutants, K119R and E220Q, lacked fork restoration ( Supplementary  Fig. 4b) . Additional experiments using Holliday junction substrates with heterology regions of 1 and 4 bases confirmed that RECQ1 has a strong branch migration activity and that its helicase activity may be important to bypass regions of heterology. However, we observed a 50% reduction in the formation of the branch migration product when the heterology region was increased from 1 to 4 bases ( Supplementary Fig. 5a,b) .
On the basis of our results showing that RECQ1 interacts with PARylated PARP1 and previous observations that the PARylation activity of PARP has a key role in mediating the accumulation of regressed forks after DNA damage 7 , we examined the effect of PARylated PARP1 on RECQ1 fork restoration activity. We found that PARylated PARP1 strongly inhibited the fork restoration rates of RECQ1: 40 nM RECQ1 converted approximately 80% of the chickenfoot structure into a replication fork structure within 20 min. Addition of an equimolar concentration of PARylated PARP1 reduced the fraction of restored fork structures to <30% ( Fig. 2c,d) . Experiments performed at increasing concentrations of PARylated PARP1 showed that a two-fold excess of PARylated PARP1 did not inhibit the reaction further, indicating that equimolar concentrations are sufficient for maximal inhibition (Supplementary Fig. 4c ). We observed a similar Fig. 5c,d) . To confirm that PARylated PARP1 is also able to inhibit the DNA unwinding activity of RECQ1, we used a fork duplex substrate with a duplex region of 20 bp ( Supplementary Fig. 5e,f) . In agreement with previous findings 29 , electrophoretic mobility shift assays using increasing concentrations of PARylated PARP1 confirmed that PARylated PARP1 binds DNA with low affinity, indicating that the inhibitory effect of PARylated PARP1 on RECQ1 activity is not due to a competition for DNA binding (Supplementary Fig. 6 ). Additional fork restoration assays performed with PAR instead of PARylated PARP1 supported this conclusion, confirming that the interaction of RECQ1 with PAR is responsible for the inhibition of the fork restoration activity (Fig. 2) .
Collectively, our biochemical data show that RECQ1 has strong fork restoration activity that could be responsible for restarting reversed forks associated with CPT treatment. PARylated PARP1 inhibits this RECQ1 activity through a process that does not involve competition for DNA binding.
To investigate whether other human RecQ helicases share this activity, we performed additional experiments with an exonuclease-deficient WRN mutant (WRN-E84A) that allows the branch migration reaction to be monitored without possible complications arising from substrate digestion. WRN-E84A promoted fork restoration and regression with similar efficiency, with a slight bias toward fork restoration (Supplementary Fig. 7) . Furthermore, the presence of PARylated PARP1 did not inhibit the fork restoration activity of WRN-E84A, in agreement with previous studies in which a different set of substrates was used 26 . These results, along with previous observations for BLM 14 , show that although other helicases are able to promote fork restoration and regression, RECQ1 has a marked preference to promote fork restoration over fork regression, and its activity is uniquely regulated by PARylated PARP1.
RECQ1 and PARP control CPT-induced replication fork slowing
Next, we used genome-wide single-molecule DNA replication assays to test whether RECQ1 depletion affects the rate of replication fork progression upon TOP1 inhibition in a cellular context. We pulselabeled U-2 OS cells with the thymidine analog CIdU for 30 min then treated cells with 50 nM CPT, concomitantly labeling them with a second thymidine analog (IdU) for an additional 30 min (Fig. 3) . We then analyzed the IdU tract-length distributions after CPT treatment with or without PARP inhibition. Using this approach, we initially confirmed previous findings that replication forks rapidly slow upon treatment with low CPT doses (50 nM), and that this effect requires the action of PARP1 (refs. 7,8) . This is consistent with the notion that PARP inactivation does not perturb normal fork progression but prevents fork slowing after TOP1 inhibition. We then measured rates of fork progression in RECQ1-depleted cells treated with CPT and the PARP inhibitor olaparib. Our results showed that PARP inhibition does not rescue CPT-induced fork slowing in RECQ1-deficient cells. These results identify an essential role for RECQ1 in the control of fork progression upon TOP1 inhibition. RECQ1 downregulation using a lentiviral system and a different RNA interference (RNAi) targeting sequence showed similar results, supporting the notion that the observed effect was specifically associated with RECQ1 loss (Fig. 4 and data not shown). Additional DNA fiber experiments showed that-in contrast to the results obtained with RECQ1-depleted cells-PARP inhibition was still able to rescue CPT-induced fork slowing in BLM-and WRN-depleted cells. These results strongly support the notion that the identified role of RECQ1 in the control of fork progression upon TOP1 inhibition reflects a specific function and not a more general role of the RecQ helicase family (Fig. 3e) . Genetic knockdown-rescue experiments confirmed that complementation in RECQ1-depleted U-2 OS cells with short hairpin RNA (shRNA)-resistant wild-type RECQ1 abrogated the effect of RECQ1 a r t i c l e s depletion on replication fork progression upon TOP1 inhibition ( Fig. 4) . Moreover, expression of the ATPase-deficient RECQ1 mutant K119R in RECQ1-depleted cells confirmed that the ATPase activity of RECQ1 is essential for its role in replication fork progression upon TOP1 inhibition (Fig. 4) . Notably, we observed a minor but statistically significant (P < 0.006) difference between the mean length of the replication tracts measured in RECQ1-depleted cells relative to luciferase-depleted cells in the absence of CPT treatment (Fig. 3b) . This is in line with our previous studies, in which we observed that the replication tracts were slightly shorter in RECQ1-depleted cells than in luciferase-depleted control cells in the absence of DNA damage 19 . These data might reflect an additional role for RECQ1 in replication fork progression in unperturbed cells.
Previous work has showed that CPT-induced fork slowing is uncoupled from DSB formation in human cells 7 . To determine whether RECQ1 depletion also influenced DSB accumulation after CPT treatment, we used a recently optimized pulsed-field gel electrophoresis (PFGE) protocol 7, 30 . Our PFGE analysis confirmed that PARP inhibition in U-2 OS cells leads to the induction of high levels of DSBs after CPT treatment (100 nM) ( Fig. 5a,b) . These results are consistent with the notion that PARP-inhibited or PARP-depleted cells do not slow or accumulate reversed forks after CPT treatment, leading to DSB formation even at low CPT doses 7 . RECQ1 depletion, however, had the opposite effect: PARP1 inhibition did not prevent fork slowing after CPT or lead to increased DSB formation in RECQ1-depleted cells (Fig. 5a,b) . As an alternative method of monitoring DSB formation, we looked at phosphorylated histone H2AX (γH2AX) and p53-binding protein 1 (53BP1) foci colocalization under the same conditions used for the PFGE experiments. In agreement with previous findings, we found that only a minor fraction of γH2AX foci colocalized with 53BP1 upon 100 nM CPT treatment and that PARP inhibition led to a considerably higher degree of γH2AX and 53BP1 colocalization 7 (Fig. 5c,d) . However, RECQ1 depletion reduced the fraction of colocalizing foci in the presence of olaparib, supporting the notion that RECQ1 depletion prevents DSB formation after PARP inhibition. Collectively, these data indicate that RECQ1 regulates the rate of replication fork progression and that RECQ1 depletion makes PARP activity dispensable in the prevention of DSB accumulation after TOP1 inhibition.
RECQ1 is essential for fork restart upon TOP1 inhibition
The observation that RECQ1 loss makes PARP activity dispensable in the prevention of fork slowing and DSB formation in CPT-treated cells suggests that regressed forks accumulate in RECQ1-depleted cells. This is in agreement with our biochemical results pointing to a role for RECQ1 in replication fork restart. To provide more direct evidence for this idea, we used EM to visualize the fine architecture of in vivo replication intermediates 31, 32 . A previous EM analysis of replication intermediates showed that replication forks undergo rapid fork reversal upon TOP1 inhibition 7 . Furthermore, effective fork reversal required PARP1 activity, possibly by promoting the accumulation or stabilization of regressed replication forks and thus preventing fork collision with a CPT-induced lesion to generate a DSB 7 . To test the hypothesis that the accumulation of reversed forks is increased in RECQ1-depleted, CPT-treated cells, we used EM to compare RECQ1-depleted, CPT-treated U-2 OS cells in which PARP was inhibited to those in which it was not inhibited (Fig. 6) . Consistent with previous findings, we observed a high frequency of fork reversal (approximately 30% of molecules analyzed) in control U-2 OS cells transfected with a small interfering RNA (siRNA) against Luc (encoding luciferase) and treated with 25 nM CPT. The same experiments performed in the presence of olaparib confirmed that PARP inhibition RECQ1-depleted cells did not result in marked reduction in the fraction of regressed forks, suggesting that regressed forks do not restart upon RECQ1 inactivation, even in the absence of PARP activity. To test this hypothesis directly, we performed recovery experiments in which we measured reversed fork frequency after CPT removal. Whereas control cells showed a marked decrease in the frequency of fork reversal (from 30% to 10%) after drug removal, RECQ1-depleted cells maintained a high frequency of reversed forks (~33%) 3 h after CPT withdrawal. These data strongly suggest that RECQ1 is essential in restarting reversed forks and indicate that the requirement of PARP for CPT-induced fork reversal reflects a unique role for PARP in limiting RECQ1-mediated fork reactivation.
DISCUSSION
Replication fork regression is rapidly emerging as a pivotal response mechanism to the induction of replication stress. This notion is supported by the recent discovery that TOP1 inhibition by CPT induces replication fork slowing and reversal, preventing DSB formation at clinically relevant doses of CPT 7, 8 . PARP1 is a crucial cellular mediator required for the accumulation or stabilization of regressed forks upon TOP1 poisoning. PARP1 itself is a target for anticancer therapies, particularly breast and ovarian cancers involving mutation of the genes BRCA1 and BRCA2. PARP inactivation prevents the accumulation of regressed forks without affecting the checkpoint response 7 . However, the mechanism by which PARP activity promotes fork reversal is still unknown, and the requirements for the restart of reversed forks have not been defined. Our work provides new insight into these mechanisms by showing that regressed forks in control cells markedly decreased the fraction of reversed forks, from 30% to <10%. RECQ1 depletion by siRNA upon CPT treatment resulted in a higher frequency of fork reversal events (~44%) than that observed in control cells. Notably, PARP inactivation in npg a r t i c l e s can restart in vivo and identifying a key role for human RECQ1 in promoting, through ATPase and branch migration activities, efficient replication fork restart after TOP1 inhibition ( Fig. 7) . Our results also show that this function of RECQ1 is not shared by other helicases, such as BLM and WRN. Furthermore, our results provide new insight into the molecular role of PARP in fork reversal by showing that the PARylation activity of PARP is important in regulating RECQ1 activity on replication forks after CPT treatment. A notable aspect of these data is that PARP activity is dispensable in the formation of reversed forks (Fig. 7a ) but required to 'accumulate' them-that is, to maintain or protect them from counteracting activity (by RECQ1) that would otherwise cause an untimely restart of reversed forks, leading to DSB formation (Fig. 7b,c) . Indeed, we show that in RECQ1-depleted cells, PARP activity is dispensable in the accumulation of reversed forks or the avoidance of CPT-induced DSBs (Fig. 7d) . We propose that PARP 'signals' the presence of lesions on the template and inhibits RECQ1 locally, thereby restraining the restart of reversed forks until repair of the TOP1 cleavage complex is complete (Fig. 7b ). An important next step will be to identify factors that modulate RECQ1-catalyzed fork restart by PARP activity. These data provide a new mechanistic insight that could help to predict the efficiency of anticancer therapies that include both PARP and TOP1 inhibitors. These combinations are now in clinical trials. Our results also suggest that RECQ1 might represent a new therapeutic target to be used in conjunction with TOP1 inhibitors. In principle, induction of fork reversal (by TOP1 poisons) and inhibition of reversed fork reactivation (by RECQ1 depletion) should synergize, which would explain the observed CPT sensitivity of RECQ1-depleted cells.
RecQ helicases are DNA unwinding enzymes essential for the maintenance of genome stability in many organisms. Why human cells should express five RecQ homologs, and microorganisms such as Escherichia coli, Saccharomyces cerevisiae and Schizosaccharomyces pombe only one or two, remains unexplained. Our previous studies provided new insight by identifying important and distinct roles for RECQ1 and RECQ4 during DNA replication 19 . These data, combined with previous observations that RECQ1 depletion leads to increased DNA damage and affects cellular proliferation 27, 33, 34 , suggest that RECQ1 might have a distinct role in the stabilization and repair of replication forks. Our discovery that RECQ1 is required for replication fork restoration after TOP1 poisoning provides what is, to our knowledge, the first indication of a specific cellular function for this RecQ helicase. U-2 OS cells lacking BLM or WRN do not show similar defects in replication fork restoration upon TOP1 poisoning, suggesting that RECQ1 is the RecQ helicase specifically responsible for promoting replication fork restart upon CPTinduced fork reversal. Moreover, RECQ1 shows a striking preference for fork restoration over regression, and its activity, unlike that of WRN, is specifically regulated by PARylation of PARP1 (ref. 26) (Supplementary Fig. 7) . However, we cannot yet rule out the possibility that other human RecQ helicases are involved in different steps of the same process.
It will be important for future studies to determine whether reversed forks are detected in response to genotoxic stress other than TOP1 inhibition and whether RECQ1 or other helicases are implicated in replication fork reversal or restart, depending on the type of DNA damage. WRN-and BLM-deficient cells show increased sensitivity to select genotoxic agents 35 , whereas RECQ1-deficient cells are markedly sensitive to CPT and etoposide, supporting the notion that these three RecQ helicases have distinct roles in replication stress response. The fact that RECQ1-depleted cells show increased sensitivity to etoposide opens the possibility that a similar mechanism of fork reversal and restart might take place upon treatment with topoisomerase II poisons. EM analysis of replication intermediates after treatment with different classes of chemotherapeutic drugs will provide early clues about combinations of drugs and RecQ helicases to pursue in future studies.
The discovery that RECQ1 is essential for fork restart upon TOP1 poisoning suggests that RECQ1 may itself be a new therapeutic target and that it could modulate the efficacy of combinatorial cancer therapies using PARP and TOP1 inhibitors that are already in clinical trials. A key experimental goal will be to determine the fate of regressed replication forks that accumulate in the absence of RECQ1. One possibility is that active replication forks are restored by the homologousrecombination machinery in the absence of the fork restart activity of RECQ1 (Fig. 7d) . Thus, RECQ1 depletion or inhibition might result in synthetic lethality in a background deficient for homologous recombination, providing a new way to target and increase the efficacy of cancer therapies when homologous-recombination repair is inefficient or inhibited.
METhODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
ACKnOwLedGMenTS
We are grateful to A. Mazin for sharing information regarding the substrate preparation. We thank P. Janscak (University of Zurich) and D. Orren (University of Kentucky College of Medicine) for providing aliquots of purified WRN and WRN-E84A proteins, respectively. We thank G. de Murcia (École Supérieure de Biotechnologie de Strasbourg) for providing the constructs for the production of the PARP1 fragment. We thank Y. Ayala for critical discussions and G. Triolo for help in recombinant protein production. We thank the Nano Research Facility of the School of Engineering and Applied Science at Washington University in St. Louis, which is part of the National Nanotechnology Infrastructure Network supported by the US National Science Foundation under grant no. ECS-0335765, for microfabrication and the use of clean-room facility. We also thank the Center for Microscopy and Image npg Double-strand break detection by pulsed-field gel electrophoresis. DSB detection by PFGE was performed as previously described with minor modifications 7, 30 .
Immunofluorescence analyses. U-2 OS cells were grown on coverslips, fixed in 3.7% PFA, permeabilized in 0.5% Triton X-100 and blocked in 3% BSA. Coverslips were then stained with rabbit polyclonal anti-53BP1 (Novus Biologicals, NB100-304) (1:500) and mouse monoclonal anti-γH2AX (Millipore, 05-636) (1:300), and detected by appropriate Alexa 488-and Alexa 594-conjugated secondary antibodies (1:700). Toto3 iodide (Life Technologies, T3604) was used as a nuclear counter-stain. Cells were imaged using a Zeiss LSM 510 Meta confocal microscope. Images were acquired using the LSM 5 software. Foci were counted with ImageJ ' Analyze particles' function and 'JACoP' plugin was used to calculate colocalization. The average number of foci was obtained from three independent experiments analyzing at least 35 cells per sample.
Electron microscopy analysis of genomic DNA in mammalian cells. EM analysis of replication intermediates has been described in detail 31, 32 , including a description of the important parameters to consider specifically for the identification and the scoring of reversed forks 32 .
